Status:
UNKNOWN
Effectiveness of Dipeptide N (2)-L-Alanyl-L-Glutamine in Trauma ICU Patients: Pilot, Prospective, Randomized and Double Blind Study.
Lead Sponsor:
Hospital Universitari Son Dureta
Conditions:
Trauma ICU Patients
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Recent reports suggest that most beneficial results of glutamine have been obtained with the parenteral administration of high doses of glutamine (0.35 g/Kg/d) and in some special group of patients, s...
Detailed Description
Objective: To evaluate the efficacy of the endovenous administration endovenous glutamine to reduce the number of infectious complications, mortality and ICU length of stay in trauma ICU patients. To ...
Eligibility Criteria
Inclusion
- Moderate to severe trauma, as defined by an Injury Severity Score (ISS) \> 10 points were included in the study.
- Traumatic patients who required enteral or parenteral nutrition during the first 48 hours after hospital admission
- Written informed consent
Exclusion
- patients whose life expectancy was less than 5 days,
- who were allergic to glutamine,
- Patients included in any other trial
- Cirrhotic patients (Child C)
- Chronic renal failure
Key Trial Info
Start Date :
October 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2012
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT01250782
Start Date
October 1 2010
End Date
October 1 2012
Last Update
December 1 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Universitario Son Dureta
Palma, Balearic Islands, Spain, 07014